Gimme Care vs Noom

Neither Gimme Care nor Noom has an FDA warning letter on record. On compounded semaglutide injection, Gimme Care costs $228 less a year at standing rates: $160 a month against $179 a month at Noom.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Gimme Care / Noom

Gimme Care logo

Gimme Care

8.5/10

Noom logo

Noom

5.8/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$160/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states and DC
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026

Neither Gimme Care nor Noom pays us. Links to them earn nothing. Scores: Gimme Care 8.5, Noom 5.8. How we are paid

What the record shows

  1. 01

    Neither Gimme Care nor Noom has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On compounded semaglutide injection, Gimme Care costs $228 less a year at standing rates: $160 a month against $179 a month at Noom.

  4. 04

    Only Gimme Care lists a price for compounded tirzepatide injection. Only Noom lists a price for brand-name tirzepatide pen.

  5. 05

    Gimme Care lists all 50 states and DC. Noom publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Gimme Care

Noom

Compounded semaglutide injection

$160/moLower

$1,920 a year

$179/mo

$2,148 a year

Compounded tirzepatide injection

$199/mo

$2,388 a year

Not sold or not priced
Brand-name tirzepatide pen
Not sold or not priced

$349/mo

$4,188 a year

Price includes
Medication, clinician visits, shipping
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly cycle
Not stated
Refunds
Full refund if canceled before the pharmacy ships; dispensed medication is final sale
Refunds only before a prescription is written; renewal charges are not refunded
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. Gimme Care: October 17, 2026. Noom: October 30, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Gimme Care

8.5/10
  • $228 a year less on compounded semaglutide injection
  • Sells compounded tirzepatide injection, which Noom does not price
  • Names no compounding pharmacy

The case for Noom

5.8/10
  • Sells brand-name tirzepatide pen, which Gimme Care does not price
  • Names no compounding pharmacy
  • Publishes no state list

Scores

Gimme Care 8.5 · Noom 5.8 out of 10. Six weighted parts.

Value25%

7.2A
vs
B
0.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

8.5A
vs
B
6.5

Accessibility10%

10.0A
vs
B
5.0

Support10%

7.0A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

Gimme Care vs Noom: questions

Neither Gimme Care nor Noom has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Gimme Care, by $228 a year at standing rates. Gimme Care: $160 a month, about $1,920 a year. Noom: $179 a month, about $2,148 a year.
Gimme Care states you can cancel at any time; refunds: full refund if canceled before the pharmacy ships; dispensed medication is final sale. Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded.
Neither Gimme Care nor Noom pays us. Links to them earn nothing. Scores: Gimme Care 8.5, Noom 5.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks